Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 6;17(1):98.
doi: 10.1186/s13195-025-01739-1.

Assessment of the relationship between synaptic density and metabotropic glutamate receptors in early Alzheimer's disease: a multi-tracer PET study

Elaheh Salardini  1   2   3 , Ryan S O'Dell  1   2 , Em Tchorz  1 , Nabeel B Nabulsi  4 , Yiyun Huang  4 , Richard E Carson  4 , Christopher H van Dyck  1   2   3   5 , Adam P Mecca  6   7
Affiliations

Assessment of the relationship between synaptic density and metabotropic glutamate receptors in early Alzheimer's disease: a multi-tracer PET study

Elaheh Salardini et al. Alzheimers Res Ther. .

Abstract

Background: The pathological effects of amyloid β oligomers (Aβo) may be mediated through the metabotropic glutamate receptor subtype 5 (mGluR5), leading to synaptic loss in Alzheimer's disease (AD). Positron emission tomography (PET) studies of mGluR5 using [18F]FPEB indicate a reduction of receptor binding that is focused in the medial temporal lobe in AD. Synaptic loss due to AD measured through synaptic vesicle glycoprotein 2A (SV2A) quantification with [11C]UCB-J PET is also focused in the medial temporal lobe, but with clear widespread reductions is commonly AD-affected neocortical regions. In this study, we used [18F]FPEB and [11C]UCB-J PET to investigate the relationship between mGluR5 and synaptic density in early AD.

Methods: Fifteen amyloid positive participants with early AD and 12 amyloid negative, cognitively normal (CN) participants underwent PET scans with both [18F]FPEB to measure mGluR5 and [11C]UCB-J to measure synaptic density. Parametric distribution volume ratio (DVR) images using equilibrium methods were generated from dynamic images. For [18F]FPEB PET, DVR was calculated using equilibrium methods and a cerebellum reference region. For [11C]UCB-J PET, DVR was calculated with a simplified reference tissue model - 2 and a whole cerebellum reference region.

Results: A strong positive correlation between mGluR5 and synaptic density was present in the hippocampus for participants with AD (r = 0.81, p < 0.001) and in the CN group (r = 0.74, p = 0.005). In the entorhinal cortex, there was a strong positive correlation between mGluR5 and synaptic density in the AD group (r = 0.85, p < 0.001), but a weaker non-significant correlation in the CN group (r = 0.36, p = 0.245). Exploratory analyses indicated more widespread significant positive correlations between synaptic density and mGluR5 within regions, as well as significant positive correlations between synaptic density in the temporal lobe and mGluR5 across a broader set of regions commonly affected by AD.

Conclusions: Our findings suggest that mGluR5 reduction in AD is closely linked to synaptic loss. Longitudinal studies are needed to clarify causality, deepen understanding of AD pathogenesis, and aid in developing novel biomarkers and treatments.

Keywords: Alzheimer’s disease; MGluR5 binding; PET; SV2A; Synaptic density; [11C]UCB-J; [18F]FPEB.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The study protocol was approved by the Yale University Human Investigation Committee and Radiation Safety Committee. All participants provided written informed consent prior to participating in the study. Consent for publication: Not applicable. Competing interests: A.P.M., R.E.C., and C.H.vD. report grants from the National Institutes of Health for the conduct of the study. A.P.M. reports grants for clinical trials from Eli Lilly and Janssen Pharmaceuticals outside the submitted work. Y.H. reports research grants from UCB and Eli Lilly outside the submitted work. Y.H., N.B.N., and R.E.C. have a patent for a newer version of the tracer. R.E.C. is a consultant for Rodin Therapeutics and has received research funding from UCB. R.E.C. reports having received grants from AstraZeneca, Astellas, Eli Lilly, Pfizer, Taisho, and UCB outside the submitted work. C.H.vD. reports consulting fees from Kyowa Kirin, Roche, Merck, Eli Lilly, and Janssen and grants for clinical trials from Biogen, Novartis, Eli Lilly, Merck, Eisai, Janssen, Roche, Genentech, Toyama, and Biohaven outside the submitted work. R.S.O. reports grants for clinical trials from Cognition Therapeutics and Bristol-Myers Squibb outside of the submitted work.

Figures

Fig. 1
Fig. 1
Correlations between mGluR5 and synaptic density in the hippocampus and entorhinal cortex [18F]FPEB (mGluR5) and [11C]UCB-J (synaptic density) DVRs are plotted for participants with CN (blue, n = 12) and AD (red, n = 15). Univariate linear regression line of best fit, Pearson’s correlation coefficients (r) and the associated p values are shown for each group for (A) hippocampus and (B) entorhinal cortex. *p < 0.05. Abbreviations: AD = Alzheimer’s disease; CN = cognitively normal; DVR = Distribution volume ratio; mGluR5 = metabotropic glutamate receptor subtype 5; PVC = partial volume correction
Fig. 2
Fig. 2
Correlation maps of mGluR5 and synaptic density in all regions Pearson’s correlation coefficients (r) and associated p values were calculated between [18F]FPEB (mGluR5) and [11C]UCB-J (synaptic density) PET DVRs in all regions in participants with (A) Alzheimer’s Disease (n = 15) and (B) normal cognition (n = 12). All voxels in each region were colored uniformly for regions that had an uncorrected p < 0.05 and displayed as an overlay on the MNI template T1 MRI. Abbreviations: AD = Alzheimer’s disease; CN = cognitively normal; DVR = Distribution volume ratio; mGluR5 = metabotropic glutamate receptor subtype 5; PVC = partial volume correction
Fig. 3
Fig. 3
Correlation matrix for mGluR5 and synaptic density (no PVC) of all regions in participants with AD The matrix displays Pearson’s correlation coefficients (r) between [18F]FPEB (mGluR5) and [11C]UCB-J (synaptic density) PET DVRs for all possible combinations of regions. Data are from 15 participants with Alzheimer’s Disease. The heat map shows the r for all combinations that had an uncorrected p < 0.05. Abbreviations: AD = Alzheimer’s disease; DVR = Distribution volume ratios; mGluR5 = metabotropic glutamate receptor subtype 5; PVC = partial volume corrected
Fig. 4
Fig. 4
Correlation matrix for mGluR5 and synaptic density (no PVC) of all regions in CN participants The matrix displays Pearson’s correlation coefficients (r) between [18F]FPEB (mGluR5) and [11C]UCB-J (synaptic density) PET DVRs for all possible combinations of regions. Data are from 12 cognitively normal participants. The heat map shows the r for all combinations that had an uncorrected p < 0.05. Abbreviations: CN = cognitively normal; DVR = Distribution volume ratios; mGluR5 = metabotropic glutamate receptor subtype 5; PVC = partial volume corrected
See this image and copyright information in PMC

Update of

References

    1. Scheff SW, DeKosky ST, Price DA. Quantitative assessment of cortical synaptic density in Alzheimer’s disease. Neurobiol Aging. 1990;11(1):29–37. - DOI - PubMed
    1. Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science. 2002;298(5594):789–91. - DOI - PubMed
    1. DeKosky ST, Scheff SW, Styren SD. Structural correlates of cognition in dementia: quantification and assessment of synapse change. Neurodegeneration. 1996;5(4):417–21. - DOI - PubMed
    1. Hamos JE, DeGennaro LJ, Drachman DA. Synaptic loss in Alzheimer’s disease and other dementias. Neurology. 1989;39(3):355–61. - DOI - PubMed
    1. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann Neurol. 1990;27(5):457–64. - DOI - PubMed

Substances

LinkOut - more resources